Status:

TERMINATED

Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge

Lead Sponsor:

John Sundy

Conditions:

Atopic Asthma

Healthy

Eligibility:

All Genders

18-40 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to identify the genes in important airway cells that are specifically expressed following inhalation of house dust mite allergen among study subjects with either allergic ...

Detailed Description

The purpose of this study is to identify the genes in airway epithelial and BAL cells that are differentially expressed following inhalation of house dust mite allergen among study subjects with aller...

Eligibility Criteria

Inclusion

  • Allergic asthmatic, or nonallergic nonasthmatic
  • Willing/able to give informed consent \& adhere to visit/protocol schedules.
  • Screening visit laboratory, C-Xray, EKG, results within normal limits
  • Women of childbearing potential must have a negative serum pregnancy test
  • Screening Pulmonary function testing above study criteria parameters

Exclusion

  • Systemic corticosteroid administration for asthma within the previous 90days
  • Antibiotic administration within the previous 30 days.
  • Viral respiratory infection within the previous 14 days.
  • Allergen immunotherapy to House dust mite within the last 10 years
  • History of severe asthma requiring intubation.
  • Occupational exposure to hay or grain dust.
  • Significant exposure history to cigarette smoke
  • Past or present history of allergen immunotherapy to within the last 10 yrs
  • Underlying illnesses that may result in altered lung function
  • Students or employees under direct supervision by protocol investigators are ineligible
  • Subjects allergic to medications used (or potentially used) in the study will be excluded.
  • Subjects using aspirin will be excluded
  • Subjects who abuse alcohol or illicit substances will be excluded
  • Medication use other than for asthma, allergies or contraception
  • Other medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
  • Nursing mothers
  • Other investigational medication within the last 30 days

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2009

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00671593

Start Date

October 1 2006

End Date

April 1 2009

Last Update

July 16 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Duke University Medical Center

Durham, North Carolina, United States, 27710